THDB0206 + insulin glargine

THDB0206 + insulin glargine is a combination therapy under investigation for the treatment of type 2 diabetes mellitus. THDB0206 is an ultra-rapid insulin formulation also referred to as BioChaperone Lispro, which incorporates insulin lispro with Adocia’s proprietary BioChaperone technology to significantly accelerate insulin absorption and action. Insulin glargine is a long-acting (basal) insulin analog that provides a steady insulin level for glycemic control. The regimen combines THDB0206 for mealtime (prandial) glucose control with insulin glargine for basal, long-acting control, aiming for comprehensive management of blood glucose in patients with type 2 diabetes[1][2][4][6].